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Summary
Sepsis is a life-threatening condition that arises as a sys-
temic inflammatory response syndrome to an infection. Its
uncontrolled progression can in frequent cases lead to mul-
tiple organ failure, which is still associated with high mor-
tality rates. Modern antibiotics made clear that the infection
is only an initiating, and not always necessary, event of this
syndrome as many patients with sepsis die despite effect-
ive eradication of the inciting pathogen. This observation
critically contributed to a paradigm shift that focused the
pathogenesis of sepsis on the host and not on the pathogen.
However, therapeutic strategies based on the inhibition of
proinflammatory critical mediators of sepsis or immunos-
timulation have so far failed to improve sepsis outcome
and, therefore, this condition urgently needs transformative
therapeutic ideas and strategies. Here we argue that the in-
duction of tolerance, a defence strategy that minimises the
impact of an infection on organ function without directly
affecting the pathogen burden, is perhaps the missing but
essential element to add to the current components of sepsis
care and treatment.
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Introduction
Based on the pressing need to better define sepsis, to enable
clinical trials and to test novel interventions for this devast-
ating condition, an international consensus panel defined
sepsis in 1992 as a systemic inflammatory response to in-
fection. The panel also proposed the term “severe sepsis”
to describe cases in which sepsis is complicated by acute
organ dysfunction, and “septic shock” for sepsis complic-
ated by hypotension that is refractory to fluid resuscitation.
The definition and characterisation of sepsis have since
evolved, but the key concepts of the original 1992 con-
sensus panel have been for the most part upheld by more
recent international consensus panels. “Severe sepsis” and
“sepsis” are sometimes now used interchangeably to de-
scribe the syndrome of infection complicated by acute or-
gan dysfunction [1, 2].
The pathophysiology and molecular bases of sepsis and
multiple organ failure remain poorly understood. As a res-
ult, the central elements of treatment (early recognition,
sepsis stratification, organ support, namely optimisation of
oxygen transport, early adequate antibiotic therapy, and
source control if necessary) have not changed substantially
in recent decades, and attempts to translate basic research
results into effective new interventions have been met with
limited or no success [3]. Therefore, perhaps not surpris-
ingly, there are currently no approved drugs that specific-
ally target sepsis. After decades without significant pro-
gress in the treatment of sepsis, there is an urgent need
for transformative therapeutic alternatives in addition to the
thoroughly tested but unsuccessful block of proinflammat-
ory mediators [4] or the more recently proposed, but so far
disappointing, stimulation of the immune response [5–8].
Innate immunity is evolutionarily ancient, crucial to fight-
ing infections by invading pathogens or other noxious chal-
lenges such as tissue injury, and relies on multiple com-
ponents, from physical barriers to effector molecules [9].
Innate immune receptors detect signatures of pathogens
(pathogen-associated molecular patterns) and also molec-
ules from diseased or dying host cells (damage-associated
molecular patterns [10]). The activation of pattern recog-
nition receptors by pathogen- or damage-associated mo-
lecular patterns initiates intracellular signalling events and
cascades leading to the expression and secretion of inflam-
matory mediators such as cytokines and chemokines. Ul-
timately, inflammation needs to be effectively terminated
after removal of the original trigger to limit tissue dam-
age and restore homeostasis [11]. Sepsis results from a de-
ranged and excessive systemic inflammatory response to
an infection, which can progress to multiple organ dysfunc-
tion and has the potential to evolve to multiple organ fail-
ure that is often fatal.
Tolerance as an emerging defence
strategy
In addition to pathogen avoidance, there are two evolution-
arily conserved defence strategies against infection that can
limit host disease severity. One relies on reducing patho-
gen load, i.e. resistance to infection that is characterised by
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and requires inflammation, while the other provides host
tissue damage control, limiting disease severity irrespect-
ively of pathogen load, i.e. tolerance to infection [12, 13].
Tissue destruction and physiological damage are a conse-
quence of mounting an immune response to fight an infec-
tion. To minimise the impact of this damage on health, a
host relies on preventive and repair pathways that will af-
fect tolerance but not necessarily resistance defences [14].
This concept of tolerance should not be confused with the
classical immunological definition of tolerance that refers
to unresponsiveness to self-antigens.
As demonstrated originally for plants and thereafter in Dro-
sophila, tolerance to infection also operates in mammals,
as revealed for Plasmodium [15, 16] and polymicrobial in-
fections in severe sepsis [17, 18]. In disease, immunopath-
ology and excessive inflammation can be the main causes
of morbidity and mortality, as immune effectors produced
during an excessive immune response and the decrease of
available energy for vital functions can cause severe and
sustained collateral damage [14]. This is particularly rel-
evant in the case of sepsis, where the effective elimination
of the original causative infection does not guarantee a fa-
vourable prognosis even with the current best standard of
care.
A therapeutic strategy solely based on the targeting of in-
flammatory pathways has been shown in multiple clinical
trials to be essentially unsuccessful [4]. The outcome of
these trials is not surprising because by the time sepsis can
be clinically diagnosed, most downstream signalling path-
ways and effectors have already been activated and inflam-
mation has already caused substantial damage. Therefore,
targeting mechanisms of tissue tolerance to damage is a vi-
able, and perhaps the critical, therapeutic option in addi-
tion to the other current pillars of sepsis management [19],
which are critical and not expected to change in the fore-
seeable future, but are also clearly insufficient.
The main problem for the clinical application of this
concept lies in our current general ignorance of the molecu-
lar mechanisms of tolerance to tissue damage [14], as very
few have so far been identified [20]. One possible strategy
to increase tolerance might be through hormesis, which
refers to the capacity of mild, sublethal stresses to protect
against larger subsequent insults [21] and can be defined as
any adaptive response exhibiting a biphasic dose response
[21]. The elicited responses can either be directly induced
or result from compensatory biological processes triggered
by an initial disruption in homeostasis, which is interest-
ing because inflammation has been considered as the ex-
treme end-result of substantial deviations of homeostasis
[22]. While diverse, hormesis responses induce wide-ran-
ging and long-lasting cytoprotective states that often con-
verge in similar mechanisms. Perhaps surprisingly, rather
than being harmful, hormesis-induced mechanisms reduce
disease susceptibility and might even prolong the lifespan
of the organism where they operate [23].
It has long been known that exposure to low levels of
bacterial lipopolysaccharide (LPS), or other inflammatory
stimuli, can desensitise the host organism and protect from
a subsequent larger dose of LPS that would otherwise be
lethal. This phenomenon is known as LPS tolerance and is
explained by the initial low dose induction of negative reg-
ulators of LPS signalling and suppression of downstream
LPS-induced tissue damage genes [24]. A role for the ox-
idative stress-induced heme oxygenase-1 in tolerance to
Plasmodium infection and other conditions causing tissue
damage [16, 25], for the induction of the unfolded protein
response (UPR) to promote tolerance to Pseudomonas aer-
uginosa infection in Caenorhabditis elegans [26], and for
the nuclear factor, erythroid 2-related factor-2 (Nrf2) gene
in cytoprotection have been recently shown. Nrf2 is a tran-
scription factor that regulates host defence against oxidat-
ive stress and inflammation-related disorders [27]. It has
anti-inflammatory effects in a LPS-induced inflammation
mouse model and its down-regulation has been associated
with higher organ failure burden and mortality in paediatric
septic shock [28]. Lactobacilli have recently been shown
to exert a hormetic protective response in the gut by indu-
cing enterocyte production of reactive oxygen species cata-
lysed by NADPH oxidase (Nox) 1, which triggers a Nr-
f2-dependent protective transcriptional response [29]. Heat
shock is known to activate another transcription factor
HSF-1 (heat shock factor 1) that prevents proteotoxicity by
triggering pathways that control refolding or degradation
of misfolded proteins [30]. Endoplasmic reticulum stress
activates a transcriptional programme, which includes the
ATF6, PERK, and IRE1 genes that restore protein homeo-
stasis in the endoplasmic reticulum [31].
In spite of these examples, hormesis mechanisms and cyto-
protective pathways remain largely unknown and unchar-
acterised. The systematic identification and characterisa-
tion of such mechanisms is likely to open a complete new
field of opportunity to understand at a molecular level
core surveillance mechanisms of basic cellular processes
with a critical role in the regulation of organ function and
whose activation can ultimately promote health and expand
longevity. The pharmacological targeting of hormetic path-
ways will be important for both the mechanistic identific-
ation of disease tolerance mechanisms and the therapeutic
targeting of diseases that are characterised by extensive tis-
sue damage or multiple organ failure.
We have recently screened approximately 2 300 com-
pounds (including most that are approved for clinical use)
for their ability to inhibit inflammatory cytokine produc-
tion and have identified members of the anthracycline fam-
ily of chemotherapeutic agents (epirubicin, doxorubicin
and daunorubicin) as potent antagonists [18]. In an exper-
imental model of severe sepsis [32], caecal ligation and
puncture (CLP), where at least 80% of C57BL/6 mice die
within 48 hours after the initial procedure, administration
of a low dose of epirubicin at the time of CLP and again 24
hours later at a total dose of 1.2 μg/g body weight reprodu-
cibly increases by 80% the survival of C57BL/6 mice sub-
jected to CLP without the use of antibiotics [18]. Protec-
tion against severe sepsis is not due to an antibiotic effect,
as epirubicin also protects C57BL/6 mice from lethal sep-
tic shock subsequent to LPS administration [18]. Moreover,
epirubicin-treated mice subjected to CLP show similar
numbers of bacteria circulating in blood and in target or-
gans of sepsis (e.g., spleen, liver and kidney) at 24 hours
post-CLP as compared with untreated controls [18]. This
suggests that epirubicin confers disease tolerance to poly-
microbial infection, a host defence strategy against infec-
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tion that acts irrespectively of pathogen burden [20]. In
fact, serum concentration of lactate dehydrogenase (lung
and general cellular damage), creatine kinase (muscle),
alanine aminotransferase (liver) and urea (kidney) are re-
duced to almost basal levels in mice treated with epirubicin
compared with untreated mice [18], suggesting that anthra-
cyclines provide tissue damage control and sustain organ
function. Ataxia telangiectasia mutated (ATM) is a mas-
ter regulator of the DNA damage response [33] and is
known to be activated by anthracyclines [34]. ATM-defi-
cient (Atm-/-) mice are not protected against CLP by epi-
rubicin and die with similar kinetics to those of wild-type
(Atm+/+) animals that are treated with phosphate-buffered
saline alone. Therefore, ATM expression is necessary to
mediate the protective effect of epirubicin [18]. Accord-
ingly, epirubicin does not normalise the serological mark-
ers of organ lesion in Atm-/- mice or decrease the levels of
inflammatory mediators.
The lung is not only the most common site of infection
leading to sepsis but also respiratory dysfunction/failure
(independently of where the infection originated) occurs
often, at a very early stage in the pathophysiology of sepsis
[35–38] and can possibly initiate a cascade of events lead-
ing to multiple organ failure that carries a very high mor-
tality rate [39].
Interestingly, key molecular steps of sepsis protection in-
duced by epirubicin, including the activation of DNA dam-
age responses and autophagy pathways, take place in the
lung [18, 40]. Their activation is necessary in the lung for
systemic protection, because depletion of ATM and ATG7
(autophagy related 7) specifically in the lung eliminates the
protection conferred by epirubicin when given systemic-
ally.
Preliminary evidence from our laboratory suggests that
lung protection is not only necessary, but also sufficient
for systemic protection as direct delivery of epirubicin to
the lung confers sepsis protection that is similar to that ob-
tained by systemic administration of the drug (Velho et al.,
unpublished). If confirmed, these observations have poten-
tial fundamental clinical significance because that would
mean that if signs of lung dysfunction are detected early
enough in patients, and necessary and effective measures
can be used, it is then possible to stop the cascade of events
leading to the domino effect causing the progressive fail-
ure of more organs, including the kidneys and liver, that
are likely to culminate in multiple organ failure, a condition
with a very poor prognosis once established [1].
Conclusion
Tolerance is an emerging defence strategy that has tre-
mendous potential to be a central element of the treatment
of sepsis and multiple organ failure as an adjuvant to the
current standard of care. Hormesis might constitute an ef-
fective possibility to induce tolerance. Interestingly, low
doses of DNA damaging agents, such as anthracyclines,
induce strong protection against mouse models of sepsis,
even in the absence of broad-spectrum antibiotics, by pro-
moting tolerance without affecting the burden of infection.
While this hormetic effect was very strong and reprodu-
cible in several mouse models of sepsis, it might not always
be applicable to real clinical settings in terms of both thera-
peutic window and organs primarily affected, because tis-
sues differ in tolerance capacity and resilience of physiolo-
gical processes. In fact, tolerance capacity varies in dif-
ferent organs and tissues as a function of their intrinsic
damage susceptibility, repair capacity, functional autonomy
and the consequences of a certain level of damage for a par-
ticular tissue. Therefore, studying how anthracyclines pro-
tect from sepsis downstream of the activation of DNA dam-
age responses might constitute an unprecedented window
into the identification of novel tolerance, cytoprotective
mechanisms and tissue damage repair mechanisms, which
are attractive molecular targets for the treatment of sepsis
and multiple organ failure. They would have the advantage
of specificity, fewer potential side effects and improved ef-
ficacy in a wide-range of clinical cases, because they can
predictably be activated at any point and severity of or-
gan dysfunction. Finally, uncovering the role of DNA dam-
age responses in sepsis also opens the possibility to under-
stand better its pathophysiology at the molecular level and
how organisms deal with stress, age and set limits to their
lifespan.
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